- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Access Insights 2023: Bill Roth Offers Insights for Chief Commercial Officers Planning a Profitable 3-5 Year Profitable Lifecycle
Blue Fin Group executive highlights how leaders can plan for immediate profitable lifecycles and beyond.
In an interview with Nicholas Saraceno, Bill Roth, SVP, Managing Partner, Blue Fin Group, discusses steps to be taken by chief commercial offers in planning for a profitable lifecycle.
Roth: The first thing you have to do is think about three things: What product archetype am I working in? What therapeutic area am I in? What drug class am I in? From there, you really ask if your therapy is novel in an unmet need area or is it a commodity. So, if you're launching a cell and gene therapy, oncology, or even in a multiple sclerosis area, it's all very different. Launching in GenMed right now is a tough one. You're looking at 60% rebates to the PBM and double digit figures to the wholesaler for distribution. By the time you stack everything on, it's hard to make money.
The hard part for chief commercial officers is how different the game is now. It's even more different than it was five years ago. Things we used to view in absolutes are not the case anymore. It's not showing up yet in the data but it is diversified.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
